Gyre Therapeutics (GYRE) Misses Q1 EPS by 3c

Gyre Therapeutics (NASDAQ: GYRE) reported Q1 EPS of ($0.10), $0.03 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $22.5 million versus the consensus estimate of $37.05 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Ionic Digital backs Texas data center audit amid grid reliability push
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low